Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZPL-5212372 in Healthy Subjects and Atopic Dermatitis
NCT02795832Phase 2Completed
- Sponsor
- Ziarco Pharma Ltd
- Start
- Jun 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zpl‑5212372 in atopic dermatitis (AD), sponsored by Ziarco Pharma Ltd. Primary endpoints: Percent Change From Baseline in Eczema Area and Severity Index at Day 14 and Percent Change From Baseline in Eczema Area and Severity Index Over Time at Day 15. Started Jun 2016; status: completed.
02
Drugs
zpl‑5212372
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02795832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02795832.